NanoSPECT/CT for Oncology Research

描述（由申请人提供）：正在申请资金购买NanoSPECT小动物SPECT（单光子发射计算机断层扫描）和CT（透射计算机断层扫描）扫描仪（biscan，华盛顿特区），用于非侵入性和纵向监测癌症和其他疾病过程，癌症，免疫和干细胞的贩运，细胞对治疗和其他干预的反应，遗传途径表达。新放射诊断和放射治疗剂在小动物（即小鼠和大鼠）模型中的肿瘤靶向和生物分布。这台最先进的仪器将安装在我们现有的小动物成像核心设施中，将成为纪念斯隆-凯特琳癌症中心（MSKCC）临床前和转化肿瘤学研究项目的重要、广泛使用的补充。像我们现有的（但技术上有限和过时的）microSPECT-microCT系统X- SPECT一样，NanoSPECT将在开发新的放射诊断和放射治疗药物（包括“抗肿瘤”抗体和其他免疫结构）、基因成像（即报告基因）系统和各种细胞和分子遗传过程的体内成像中发挥关键作用，这对我们了解癌症的自然史及其对各种疗法的反应至关重要。因此，迫切需要为一种新的、功能更强大的微spect -微ct系统（NanoSPECT）提供资金，以增强和扩展我们的体内放射性核素成像能力，并提供更多定量可靠的三维（层析）体内放射性核素成像能力。与我们过时的X-SPECT相比，NanoSPECT的关键优势包括：(1)更高的灵敏度，在更短的成像时间内产生更高质量，更定量准确的图像；(2)进行全身超高分辨率针孔SPECT研究的能力，在一次研究中提供全身生物分布数据和可识别的解剖信息；(3)成像高能单光子发射器的能力，如碘-131 (131I)，这是一种广泛使用且重要的“治疗”放射性核素，X-SPECT无法成像。除了许多有科学计划的资助项目外，我们的设施和我们的中心还拥有完善的技术和科学专业知识，可以在安装后充分和立即利用该仪器，并拥有高效的行政和财务基础设施，以支持和维护该仪器及其长期有效使用。

DESCRIPTION (provided by applicant): Funds are being requested to purchase a NanoSPECT small-animal SPECT (single-photon emission computed tomography) and CT (transmission computed tomography) scanner (Bioscan, Washington, DC) for non-invasively and longitudinally monitoring cancer and other disease processes, trafficking of cancer, immune, and stem cells, cellular responses to therapy and other interventions, genetic pathway expression, and tumor targeting and biodistribution of new radio diagnostic and radio therapeutic agents in small-animal (i.e. mouse and rat) models. This state-of-the-art instrument, to be installed in our existing Small-Animal Imaging Core Facility, will be a critical, broadly used addition to the pre-clinical and translational oncology research program at Memorial Sloan-Kettering Cancer Center (MSKCC). Like our existing (but technically limited and outdated) microSPECT-microCT system, the X- SPECT, the NanoSPECT will play a critical role in the development of novel radio diagnostic and radio therapeutic agents (including "anti-tumor" antibodies and other immune constructs), gene imaging (i.e. reporter gene) systems and in vivo imaging of various cellular and molecular-genetic processes critical to our understanding of the natural history of cancer and its response to various therapies. Funds for a new, far more functional microSPECT-microCT system, the NanoSPECT, are therefore urgently requested to enhance and expand our in vivo radionuclide imaging capabilities and to provide more quantitatively reliable three-dimensional (tomographic) in vivo radionuclide imaging capability. Among the critical advantages of the NanoSPECT over our outdated X-SPECT are: (1) substantially higher sensitivity, yielding higher quality, more quantitatively accurate images in shorter imaging times; (2) the capability of performing whole-body ultra-high-resolution pinhole SPECT studies, providing whole-body biodistribution data and recognizable anatomic information in a single study; and (3) the capability to image high-energy single- photon emitters such as iodine-131 (131I), a widely used and important "therapeutic" radionuclide not image-able with the X-SPECT. In addition to numerous funded projects with scientific plans in place to use the NanoSPECT, our Facility and our Center have well-established technical and scientific expertise to fully and immediately utilize this instrument upon its installation and a highly efficient administrative and financial infrastructure in place to support and maintain this instrument and its effective use long-term.